Document is current
Any future updates will be listed below
-
Authors
Strom, Nora I. https://orcid.org/0000-0002-5261-8852
Burton, Christie L. https://orcid.org/0000-0002-8955-6528
Iyegbe, Conrad
Silzer, Talisa
Antonyan, Lilit
Pool, René https://orcid.org/0000-0001-5579-0933
Lemire, Mathieu
Crowley, James J. https://orcid.org/0000-0001-9051-1557
Hottenga, Jouke-Jan https://orcid.org/0000-0002-5668-2368
Ivanov, Volen Z.
Larsson, Henrik https://orcid.org/0000-0002-6851-3297
Lichtenstein, Paul https://orcid.org/0000-0003-3037-5287
Magnusson, Patrik https://orcid.org/0000-0002-7315-7899
Rück, Christian https://orcid.org/0000-0002-8742-0168
Schachar, Russell
Wu, Hei Man https://orcid.org/0000-0003-1559-7586
Cath, Danielle
Crosbie, Jennifer
Mataix-Cols, David https://orcid.org/0000-0002-4545-0924
Boomsma, Dorret I. https://orcid.org/0000-0002-7099-7972
Mattheisen, Manuel https://orcid.org/0000-0002-8442-493X
Meier, Sandra M.
Smit, Dirk J. A. https://orcid.org/0000-0001-8301-8860
Arnold, Paul D. https://orcid.org/0000-0003-2496-4624
- License Information
-
More Information
Article History
Received: 15 November 2022
Revised: 18 January 2024
Accepted: 15 February 2024
First Online: 28 March 2024
Competing interests
: DM-C receives royalties for contributing articles to UpToDate, Wolters Kluwer Health, outside of the submitted work. RJS has consulted to E. Lilly, Highland Therapeutics and eHave. HL reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. HL is editorin-chief of JCPP Advances. PA receives research funding from Biohaven Pharmaceuticals, unrelated to the submitted work. All other authors report no potential conflict of interest.
